抗甲氧苯青黴素金黃色葡萄球菌(Methicilin-resistant Staphylococcus aureus) 是院內肺炎常見之菌種之一，但現今臨床醫師一直為糖肽類抗生素(glycopeptides) 治療methicilin-resistantStaphylococcus aureus (MRSA) 肺炎的高失敗率所困擾；因此，新一代可對抗MRSA 的抗生素（linezolid）是否可用於肺炎令人寄予厚望，本篇綜論就此議題作進一步的整理。近年來，部分研究比較利奈唑胺(linezolid) 與萬古黴素(vancomycin) 運用於MRSA 肺炎治療之效果，其顯示linezolid 的臨床治癒率、存活率和細菌清除率似乎高於vancomycin；但是最近的兩篇統合分析(meta-analysis) 卻又發現兩者在臨床治癒率、存活率和細菌清除率卻沒有統計學上之差別。因此，目前仍需更進一步的隨機對照組試驗(randomized controlled trial, RCT) 提供更多資訊以釐清何者對MRSA 肺炎的臨床效益較佳。

Methicilin-resistant Staphylococcus aureus is one of common pathogen in nosocomial pneumonia. Higher failure rate of treatment in methicilin-resistant Staphylococcus aureus (MRSA) pneumonia has been a major
challenge for clinical physicians. Whether new antibiotics (linezolid) for MRSA could treat pneumonia is expected greatly. Recent studies of comparing linezolid versus vancomycin in the treatment of MRSA pneumonia revealed that the rates of clinical cure, survival and microbiological eradication seem to be higher in linezolid group. But recent two meta-analysis disclose no significant difference of clinical cure, survival and bacterial response between these two antibiotics. Further randomized, controlled trials (RCT) would be needed to provide more information on
clinical efficacy of these antibiotics for MRSA pneumonia.